|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Identifier | Location | Start/End | Phase | Stem Cells used | Mechanism/Drug | Route of administration | Primary outcome measures | Reference |
| NCT01172964 | City of Hope Medical Center, CA, USA | 8/2010-2/2015 | Pilot | HB1.F3.CD | Enzyme/Prodrug, Cytosine Deaminase/5-FC | Surgical cavity | Determine safety and feasibility of intracerebral administration of HB1.F3.CD in combination with oral 5-FC | Portnow et al., 2017 |
| NCT02015819 | City of Hope Medical Center, CA, USA | 10/2014-6/2019 | I | HB1.F3.CD | Enzyme/Prodrug, Cytosine Deaminase/5-FC, Leucovorin | Surgical cavity and additional doses intraventricular via a Rickham catheter | Define the optimal dose of NSC-CD in combination with 5-FC and leucovorin; To determine feasibility of multiple NSC-CD doses. | N/A |
| NCT03072134 | Northwestern University, IL, USA | 4/2017-12/2021 | I | NSC-CRAd-Survivin-pk7 | Oncolytic virus | Surgical cavity | Evaluate safety of NSC-OV in combination with chemotherapy; Determine MTD. | N/A |
| NCT03896568 | M.D. Anderson Cancer Center, TX, USA | 2/2019-5/2022 | I | BM-hMSCs-DNX2401 | Oncolytic virus | intra-arterial injection (transfemoral super-selective endovascular intracranial injection) | Determine MTD; Determine local and systemic toxicity of BM-hMSCs-DNX2401; Determine expression and distribution of adenoviral particles | N/A |
| NCT04657315 | CHA University, South Korea | 3/2021-12/2022 | I | MSC11FCD | Enzyme/Prodrug, Cytosine Deaminase/5-FC | Intratumoral | Determine MTD;5-FC, 5-FU concentration in the blood; MSC11FCD concentrations; Treatment-related AE | N/A |

**Table S2:** Current clinical trials using Stem Cells for the treatment of Glioblastoma (clinical trials.org, 3/18/21)

Abbreviations: MTD: maximum tolerated dose, 5-FC: 5-Fluorocytosine, 5-FU: 5-Fluorouracil, AE: Adverse effects